Literature DB >> 22180437

Assessment of dysplastic hematopoiesis: lessons from healthy bone marrow donors.

Stefani Parmentier1, Johannes Schetelig, Kerstin Lorenz, Michael Kramer, Robin Ireland, Ulrich Schuler, Rainer Ordemann, Gabi Rall, Markus Schaich, Martin Bornhäuser, Gerhard Ehninger, Frank Kroschinsky.   

Abstract

BACKGROUND: According to WHO 2008 guidelines, the required percentage of cells manifesting dysplasia in the bone marrow to qualify as significant is 10% or over in one or more hematopoietic cell lineages, but this threshold is controversial. No 'normal' values have been established. Therefore, we investigated dyshematopoiesis in bone marrow aspirate squash preparations of 120 healthy bone marrow donors. DESIGN AND METHODS: Bone marrow squash slides of 120 healthy unrelated bone marrow donors were examined independently by 4 experienced morphologists. Samples were taken from the first aspiration during the harvest. Bone marrow preparation and assessment were performed according to WHO recommendations and ICSH guidelines.
RESULTS: More than 10% dysmyelopoiesis could be detected in 46% of bone marrow aspirate squash preparations with 26% in 2 or more cell lineages and 7% in 3 cell lineages in healthy bone marrow donors. Donors under the age of 30 years exhibited more dysgranulopoietic changes and dysmegakaryopoietic changes (P<0.001) compared to the older donors. Female donors showed more dysgranulopoietic changes than male donors (P = 0.025). The concordance rate between the 4 investigators was modest in dysgranulopoiesis but poor in dyserythropoiesis and dysmegakaryopoiesis.
CONCLUSIONS: The poor reliability of the 10% cut off was partly related to the proximity of the current criteria to the observed cut-off mean values of the normal population. These findings question the current WHO threshold of the 10% or over necessary for the percentage of cells manifesting dysplasia to be considered significant, and suggest that either a higher threshold would be more appropriate or different thresholds should be set for each lineage.

Entities:  

Mesh:

Year:  2011        PMID: 22180437      PMCID: PMC3342975          DOI: 10.3324/haematol.2011.056879

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  30 in total

1.  Severe dyserythropoiesis and autoimmune thrombocytopenia associated with ingestion of kelp supplements.

Authors:  K G Pye; S M Kelsey; I M House; A C Newland
Journal:  Lancet       Date:  1992-06-20       Impact factor: 79.321

Review 2.  The epidemiology of myelodysplastic syndromes.

Authors:  Mikkael A Sekeres
Journal:  Hematol Oncol Clin North Am       Date:  2010-04       Impact factor: 3.722

3.  Observations on the haemopoietic response to critical illness.

Authors:  R J Amos; M Deane; C Ferguson; G Jeffries; C J Hinds; J A Amess
Journal:  J Clin Pathol       Date:  1990-10       Impact factor: 3.411

4.  Congenital erythropoietic porphyria, diminished activity of uroporphyrinogen decarboxylase and dyserythropoiesis.

Authors:  J P Kushner; N R Pimstone; C R Kjeldsberg; M A Pryor; A Huntley
Journal:  Blood       Date:  1982-04       Impact factor: 22.113

5.  Are 'dysplastic' and hypogranular megakaryocytes specific markers for myelodysplastic syndrome?

Authors:  K F Wong; J K Chan
Journal:  Br J Haematol       Date:  1991-04       Impact factor: 6.998

6.  Arsenic intoxication as a cause of megaloblastic anemia.

Authors:  D D Westhoff; R J Samaha; A Barnes
Journal:  Blood       Date:  1975-02       Impact factor: 22.113

7.  Copper deficiency masquerading as myelodysplastic syndrome.

Authors:  Xylina T Gregg; Vishnu Reddy; Josef T Prchal
Journal:  Blood       Date:  2002-08-15       Impact factor: 22.113

8.  Alcohol-associated pancytopenia with hypocellular bone marrow.

Authors:  H S Ballard
Journal:  Am J Clin Pathol       Date:  1980-06       Impact factor: 2.493

9.  Evaluation of the dysmyelopoiesis in 336 patients with de novo acute myeloid leukemia: major importance of dysgranulopoiesis for remission and survival.

Authors:  J E Goasguen; T Matsuo; C Cox; J M Bennett
Journal:  Leukemia       Date:  1992-06       Impact factor: 11.528

10.  Alcohol-induced bone marrow damage. A bone marrow study in alcohol-dependent individuals.

Authors:  F Michot; J Gut
Journal:  Acta Haematol       Date:  1987       Impact factor: 2.195

View more
  25 in total

1.  Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes.

Authors:  David P Steensma; Rafael Bejar; Siddhartha Jaiswal; R Coleman Lindsley; Mikkael A Sekeres; Robert P Hasserjian; Benjamin L Ebert
Journal:  Blood       Date:  2015-04-30       Impact factor: 22.113

2.  Mutational landscape and response are conserved in peripheral blood of AML and MDS patients during decitabine therapy.

Authors:  Eric J Duncavage; Geoffrey L Uy; Allegra A Petti; Christopher A Miller; Yi-Shan Lee; Bevan Tandon; Feng Gao; Catrina C Fronick; Michelle O'Laughlin; Robert S Fulton; Richard K Wilson; Meagan A Jacoby; Amanda F Cashen; Lukas D Wartman; Matthew J Walter; Peter Westervelt; Daniel C Link; John F DiPersio; Timothy J Ley; John S Welch
Journal:  Blood       Date:  2017-01-12       Impact factor: 22.113

3.  Morphological classification of the myelodysplastic syndromes: how much more education of diagnosticians is necessary?

Authors:  John M Bennett
Journal:  Haematologica       Date:  2013-04       Impact factor: 9.941

4.  Are mild/moderate acquired idiopathic aplastic anaemia and low-risk myelodysplastic syndrome one or two diseases or both and how should it/they be treated?

Authors:  S Nakao; R P Gale
Journal:  Leukemia       Date:  2016-09-02       Impact factor: 11.528

Review 5.  Nuances of Morphology in Myelodysplastic Diseases in the Age of Molecular Diagnostics.

Authors:  Aaron C Shaver; Adam C Seegmiller
Journal:  Curr Hematol Malig Rep       Date:  2017-10       Impact factor: 3.952

Review 6.  Revisiting the case for genetically engineered mouse models in human myelodysplastic syndrome research.

Authors:  Ting Zhou; Marsha C Kinney; Linda M Scott; Sandra S Zinkel; Vivienne I Rebel
Journal:  Blood       Date:  2015-06-15       Impact factor: 22.113

7.  Immunophenotypic analysis of erythroid dysplasia in myelodysplastic syndromes. A report from the IMDSFlow working group.

Authors:  Theresia M Westers; Eline M P Cremers; Uta Oelschlaegel; Ulrika Johansson; Peter Bettelheim; Sergio Matarraz; Alberto Orfao; Bijan Moshaver; Lisa Eidenschink Brodersen; Michael R Loken; Denise A Wells; Dolores Subirá; Matthew Cullen; Jeroen G Te Marvelde; Vincent H J van der Velden; Frank W M B Preijers; Sung-Chao Chu; Jean Feuillard; Estelle Guérin; Katherina Psarra; Anna Porwit; Leonie Saft; Robin Ireland; Timothy Milne; Marie C Béné; Birgit I Witte; Matteo G Della Porta; Wolfgang Kern; Arjan A van de Loosdrecht
Journal:  Haematologica       Date:  2016-10-06       Impact factor: 9.941

8.  Minimal morphological criteria for defining bone marrow dysplasia: a basis for clinical implementation of WHO classification of myelodysplastic syndromes.

Authors:  M G Della Porta; E Travaglino; E Boveri; M Ponzoni; L Malcovati; E Papaemmanuil; G M Rigolin; C Pascutto; G Croci; U Gianelli; R Milani; I Ambaglio; C Elena; M Ubezio; M C Da Via'; E Bono; D Pietra; F Quaglia; R Bastia; V Ferretti; A Cuneo; E Morra; P J Campbell; A Orazi; R Invernizzi; M Cazzola
Journal:  Leukemia       Date:  2014-05-20       Impact factor: 11.528

9.  Reproducibility of the World Health Organization 2008 criteria for myelodysplastic syndromes.

Authors:  Leonor Senent; Leonor Arenillas; Elisa Luño; Juan C Ruiz; Guillermo Sanz; Lourdes Florensa
Journal:  Haematologica       Date:  2012-10-12       Impact factor: 9.941

Review 10.  Border between aplastic anemia and myelodysplastic syndrome.

Authors:  Hirohito Yamazaki; Shinji Nakao
Journal:  Int J Hematol       Date:  2013-04-24       Impact factor: 2.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.